Exon-skipping therapy for Duchenne muscular dystrophy

The Lancet

Volumn 379, Issue 9811, 2012, Pages

  Bhagavati, Satyakam ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; MESSENGER RNA; RIBONUCLEASE; MORPHOLINE DERIVATIVE; OLIGONUCLEOTIDE;

CODON; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; EXON; GENETICS; MALE; METABOLISM; NOTE;

DYSTROPHIN; EXONS; HUMANS; MALE; MORPHOLINES; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES;

EID: 84855841414     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60063-4     Document Type: Letter

References (5)

1. S Cirak, V Arechavala-Gomeza, M Guglieri et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open label, phase 2, dose-escalation study Lancet 378 2011 595 605
2. JM Fritschy Is my antibody-staining specific? How to deal with the pitfalls of immunohistochemistry Eur J Neurosci 28 2008 2365 2370
3. A Schaffer-Alegria, A Lodge, K Vattem Performing and optimizing Western blots with an emphasis on chemiluminescent detection Methods Enzymol 463 2009 573 599
4. J Chelly, H Gilgenkrantz, M Lambert et al. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies Cell 63 1990 1239 1248 (Pubitemid 120035072)
5. J Wen, S Brogna Nonsense-mediated mRNA decay Biochem Soc Trans 36 2008 514 516 (Pubitemid 351839366)